# Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

> **NCT05013099** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ImaginAb, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Melanoma
- Merkel Cell Carcinoma, Unspecified
- Renal Cell Carcinoma
- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** zirconium Zr 89 crefmirlimab berdoxam

## Key facts

- **NCT ID:** NCT05013099
- **Lead sponsor:** ImaginAb, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-09
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013099, "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05013099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*